EVO-022

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameEVO-022
Drug Alias Nameestrogen antagonist combination (Evolve Oncology)EVO-022
ClassificationSmall molecules
Mechanisms of ActionEstrogen receptor alpha degraders
TargetsEstrogen receptor alpha
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesEvolve Oncology
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEvolve Oncology
Active IndicationsN/A
Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A